


New and Novel Tools For Cancer Research




P5091

P5091

Selective inhibitor of the ubiquitin-specific protease USP7 ($IC_{50}=4.2 \mu M$)^{1,2}. Induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance¹. Displays antiangiogenesis activity *in vivo*².

10-1422

5 mg, 25 mg




ML-239

ML-239

Cancer stem cells (CSC) are resistant to standard cancer treatments. ML-239 was discovered in a screen using CSC-like cells created by inducing human breast epithelial cells into an epithelial-to-mesenchymal transdifferentiated state. ML-239 was found to be selectively toxic to these cells ($IC_{50}=1.2 \mu M$)³. Although its direct target has not yet been identified ML-239 is an important tool for research in selective killing of CSCs.

10-1417

5 mg, 25 mg




Dynasore

CZC-54252

Potent inhibitor of the leucine-rich repeat kinase 2 (LRRK2). $IC_{50}=1.28 \text{ nM}$ and 1.85 nM for wild type and G2019S mutant respectively⁴.

10-1421

5 mg, 25 mg



KY-02111

Dynasore

Dynasore, a highly selective dynamin inhibitor (GTPase activity), suppresses lamellipodia formation and cancer cell invasion by destabilizing actin filaments⁵.

10-1427

5 mg, 25 mg

KY-02111

Inhibits Wnt signaling but in a manner that is distinct from previously described Wnt inhibitors⁶. Promotes cardiac differentiation of human pluripotent stem cells.

10-1437

5 mg, 25 mg

References

1. D Chauhan, *et al.* 2012 *Cancer Cell* 22 345
2. J Weinstock, *et al.* 2012 *ACS Med. Chem. Lett.* 3 789
3. LC Carmody, *et al.* 2012 *J. Biomol. Screening* 17 1204
4. N Ramsden, *et al.* 2011 *ACS Chem. Biol.* 6 1021
5. H Yamada, *et al.* 2009 *Biochem. Biophys. Res. Commun.* 390 1142
6. I Minami, *et al.* 2012 *Cell Rep.* 2 1448